CAC
DMAQR

Cowen and Company’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

Cowen and Company’s Portfolio DMAQR Stock Details DMAQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-553,167
Closed -$166K – 793
2023
Q4 		$166K Sell
553,167
-118,047
-18% -$36.5K 0.01% 220
2023
Q3 		$234K Buy
671,214
+608,854
+976% +$160K 0.02% 205
2023
Q2 		$9.98K Sell
62,360
-1,903,470
-97% -$311K ﹤0.01% 392
2023
Q1 		$285K Sell
1,965,830
-236,838
-11% -$24K 0.03% 136
2022
Q4 		$132K Buy
2,202,668
+14,517
+0.7% +$830 0.01% 193
2022
Q3 		$85K Buy
2,188,151
+445,852
+26% +$49.3K 0.01% 233
2022
Q2 		$192K Buy
1,742,299
+90,700
+5% +$14.8K 0.02% 211
2022
Q1 		$297K Buy
1,651,599
+570,348
+53% +$144K 0.03% 197
2021
Q4 		$346K Buy
+1,081,251
New +$342K 0.03% 257

Cowen and Company's DMAQR Position: Q1 2024 in Review

Cowen and Company sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q1 2024, closing a stake of 553,167 shares — an estimated $166K sold.

Cowen and Company first reported a position in DMAQR in Q4 2021 and held it in 9 quarters. The position peaked at $346K in Q4 2021. 0 funds tracked by Wall St. Rank hold DMAQR as of Q1 2024.

  • Cowen and Company reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 553,167 Deep Medicine Acquisition Corp. Rights shares in Q1 2024, an estimated $166K.
  • Cowen and Company first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 9 quarters.
  • Cowen and Company's Deep Medicine Acquisition Corp. Rights position peaked at $346K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.